Altesa BioSciences Initiates Phase IIb CARDINAL Trial for COPD Treatment
Altesa BioSciences begins global CARDINAL trial to assess antiviral vapendavir for improving symptoms and lung function in COPD patients.
Clinical Trial Phase 2b | 06/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy